Clearstead Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $29.2M | Buy |
134,159
+32,397
| +32% | +$7.19M | 0.27% | 75 |
|
|
2025
Q4 | $23.3M | Buy |
101,762
+343
| +0.3% | +$78.1K | 0.29% | 69 |
|
|
2025
Q3 | $23.5M | Sell |
101,419
-1,043
| -1% | -$212K | 0.31% | 64 |
|
|
2025
Q2 | $19M | Buy |
102,462
+2,779
| +3% | +$516K | 0.27% | 86 |
|
|
2025
Q1 | $20.9M | Sell |
99,683
-390
| -0.4% | -$75.8K | 0.32% | 71 |
|
|
2024
Q4 | $17.8M | Sell |
100,073
-384
| -0.4% | -$70.6K | 0.27% | 88 |
|
|
2024
Q3 | $19.8M | Buy |
100,457
+2,001
| +2% | +$373K | 0.31% | 76 |
|
|
2024
Q2 | $16.9M | Buy |
98,456
+44,861
| +84% | +$7.43M | 0.29% | 77 |
|
|
2024
Q1 | $8.64M | Sell |
53,595
-636
| -1% | -$110K | 0.43% | 48 |
|
|
2023
Q4 | $8.4M | Sell |
54,231
-68,078
| -56% | -$9.93M | 0.45% | 43 |
|
|
2023
Q3 | $18.2M | Buy |
122,309
+69,699
| +132% | +$10.2M | 0.53% | 44 |
|
|
2023
Q2 | $7.09M | Buy |
52,610
+6,017
| +13% | +$882K | 0.43% | 48 |
|
|
2023
Q1 | $7.43M | Buy |
46,593
+911
| +2% | +$139K | 0.54% | 38 |
|
|
2022
Q4 | $7.38M | Sell |
45,682
-2,013
| -4% | -$309K | 0.58% | 37 |
|
|
2022
Q3 | $6.4M | Sell |
47,695
-13,655
| -22% | -$1.96M | 0.59% | 35 |
|
|
2022
Q2 | $9.4M | Buy |
61,350
+422
| +0.7% | +$64.5K | 0.73% | 31 |
|
|
2022
Q1 | $9.88M | Buy |
60,928
+746
| +1% | +$108K | 0.67% | 29 |
|
|
2021
Q4 | $8.15M | Buy |
60,182
+2,451
| +4% | +$290K | 0.55% | 36 |
|
|
2021
Q3 | $6.23M | Buy |
57,731
+3,469
| +6% | +$396K | 0.46% | 46 |
|
|
2021
Q2 | $6.11M | Buy |
54,262
+577
| +1% | +$65K | 0.47% | 46 |
|
|
2021
Q1 | $5.81M | Buy |
53,685
+5,517
| +11% | +$590K | 0.48% | 44 |
|
|
2020
Q4 | $5.16M | Buy |
48,168
+9,890
| +26% | +$950K | 0.47% | 46 |
|
|
2020
Q3 | $3.35M | Buy |
38,278
+771
| +2% | +$72.6K | 0.36% | 62 |
|
|
2020
Q2 | $3.68M | Buy |
37,507
+10,834
| +41% | +$954K | 0.43% | 54 |
|
|
2020
Q1 | $2.03M | Sell |
26,673
-2,097
| -7% | -$179K | 0.3% | 68 |
|
|
2019
Q4 | $2.55M | Sell |
28,770
-180
| -0.6% | -$14.9K | 0.31% | 70 |
|
|
2019
Q3 | $2.19M | Sell |
28,950
-3,009
| -9% | -$206K | 0.29% | 71 |
|
|
2019
Q2 | $2.32M | Buy |
31,959
+577
| +2% | +$45.4K | 0.31% | 66 |
|
|
2019
Q1 | $2.53M | Sell |
31,382
-4,703
| -13% | -$385K | 0.35% | 63 |
|
|
2018
Q4 | $3.33M | Sell |
36,085
-909
| -2% | -$79.9K | 0.52% | 51 |
|
|
2018
Q3 | $3.5M | Buy |
36,994
+425
| +1% | +$40.3K | 0.48% | 48 |
|
|
2018
Q2 | $3.39M | Buy |
36,569
+1,321
| +4% | +$129K | 0.48% | 46 |
|
|
2018
Q1 | $3.34M | Sell |
35,248
-1,575
| -4% | -$173K | 0.48% | 46 |
|
|
2017
Q4 | $3.56M | Sell |
36,823
-4,113
| -10% | -$388K | 0.48% | 47 |
|
|
2017
Q3 | $3.64M | Sell |
40,936
-302
| -0.7% | -$23K | 0.47% | 51 |
|
|
2017
Q2 | $2.99M | Buy |
41,238
+5,092
| +14% | +$342K | 0.44% | 53 |
|
|
2017
Q1 | $2.35M | Buy |
36,146
+3,268
| +10% | +$205K | 0.34% | 59 |
|
|
2016
Q4 | $2.06M | Buy |
+32,878
| New | +$2.01M | 0.33% | 55 |
|
Other funds holding ABBV
VCM
VPM
Clearstead Advisors's ABBV Position: Q1 2026 in Review
Clearstead Advisors increased its AbbVie (ABBV) stake by 32% in Q1 2026, buying an estimated $7.19M and bringing the position to 134,159 shares worth $29.2M. The position accounts for 0.27% of the portfolio, ranked #75.
Clearstead Advisors first reported a position in ABBV in Q4 2016 and has held it in 38 quarters since. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Clearstead Advisors held 134,159 shares of AbbVie worth $29.2M as of Q1 2026.
- Clearstead Advisors bought 32,397 AbbVie shares in Q1 2026, an estimated $7.19M.
- AbbVie made up 0.27% of Clearstead Advisors's portfolio in Q1 2026, its #75 holding.
- Clearstead Advisors first reported a position in AbbVie in Q4 2016 and has held it in 38 quarters since.
- 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Clearstead Advisors's 13F filing for Q1 2026, filed 6 May 2026.